• Explore /
  • Poster
  • / Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).

Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).

Abstract Poster

Authors

null

Patrick M Boland

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Patrick M Boland , Sarbajit Mukherjee , Iman Imanirad , Namrata Vijayvergia , Seth D. Cohen , Medhavi Gupta , Renuka V. Iyer , Sarah Chatley , Beth Cahill , Deepak Vadehra , Kristopher Attwood , Howard S. Hochster , Christos Fountzilas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT04109924

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3590)

DOI

10.1200/JCO.2023.41.16_suppl.3590

Abstract #

3590

Poster Bd #

290

Abstract Disclosures

Similar Posters

First Author: Antoine Adenis

First Author: Hideaki Bando

First Author: Zev A. Wainberg

First Author: Zev A. Wainberg